Retrospective study of the efficacy of vedolizumab in patients with inflammatory bowel disease
10.12092/j.issn.1009-2501.2024.08.007
- VernacularTitle:维得利珠单抗治疗炎症性肠病患者疗效评价的回顾性研究
- Author:
Peipei LI
1
;
Yue WU
;
Xianzheng ZHANG
;
Lingling ZHANG
Author Information
1. 安徽中医药大学第一附属医院药学部
- Keywords:
inflammatory bowel disease;
vedoli-zumab;
efficacy;
safety
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(8):899-906
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To evaluate the efficacy and safe-ty of vedolizumab in the treatment of inflammato-ry bowel disease.METHODS:The clinical data of 25 patients with inflammatory bowel disease(IBD)(13 ulcerative colitis(UC)and 12 Crohn's disease(CD))treated with vedolizumab(VDZ)in the Anorectal department of our hospital from July 2020 to Au-gust 2023 were retrospectively collected.VDZ 300 mg was given intravenously at weeks 0,2 and 6 to induce remission,and 300 mg was given intrave-nously every 8 weeks to maintain remission.The evaluation was carried out after 30 weeks of treat-ment.The primary efficacy indicators included clini-cal response rate,clinical remission rate,and endo-scopic remission rate.The secondary efficacy indi-cators included nutritional status indicators(body weight(Wt),hemoglobin(HGB),albumin(ALB),he-matocrit(HCT)),inflammation degree indicators(high-sensitivity C-reactive protein(hs-CRP),eryth-rocyte sedimentation rate(ESR)).All adverse reac-tions that occurred during VDZ treatment were re-corded.RESULTS:The total clinical response rate of IBD patients treated with VDZ for 6 weeks and 14 weeks was 32％and 60％,respectively.The total clinical remission rate of IBD patients treated with VDZ for 14 weeks and 30 weeks was 16％and 36％,respectively.There was no significant difference in clinical response rate and clinical remission rate be-tween UC and CD treated with VDZ(P＞0.05).After 30 weeks of treatment,the body weight of UC pa-tients was significantly increased,the levels of HCT％,ALB and HGB were significantly improved,and the level of ESR was significantly decreased.Af-ter 30 weeks of treatment,the body weight of CD patients increased significantly,and the inflamma-tory index hs-CRP,nutritional index HCT％,ALB and HGB levels were significantly improved.One pa-tient had an increase in white blood cell count af-ter the third infusion of VDZ,and no other adverse reactions occurred.CONCLUSION:As an induction and maintenance therapy for IBD patients,VDZ can alleviate intestinal inflammation,relieve clinical symptoms,improve nutritional status and improve quality of life of patients,with high safety.
